How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
Characterizing the Theranostic Potential of DLL3-targeting Agents in High-grade Neuroendocrine Carcinomas of the Lung and Prostate
Description:
The purpose of this study is to find out whether 177Lu-DTPA-SC16.56 is a safe treatment for people with small-cell lung cancer or neuroendocrine prostate cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Contacts:
Michael Morris, MDmorrism@mskcc.org
646-422-4471
Lisa Bodei, MD, PhDbodeil@mskcc.org
212-639-7373
Government Study Link:
NCT06941480 - Click here to see study onClinicalTrials.gov
177Lu-DTPA-SC16.56
Isotope(s):
Target(s):
- DLL3
